DiaMedica Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 10 - Net Loss Per Share

Note 10 - Net Loss Per Share

3 Months Ended

Mar. 31, 2021

10.	Net Loss Per Share

We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.

The following table summarizes our calculation of net loss per common share for the periods (in thousands, except share and per share data):

	Three Months Ended March 31,
	2021			2020
Net loss	$	(3,622	)	$	(2,425	)
Weighted average shares outstanding—basic and diluted		18,766,656			13,107,725
Basic and diluted net loss per share	$	(0.19	)	$	(0.19	)

The following outstanding potential common shares were

not

included in the diluted net loss per share calculations as their effects were

not

dilutive:

	Three Months Ended March 31,
	2021		2020
Employee and non-employee stock options		1,421,094		1,181,309
Common shares issuable under common share purchase warrants		265,000		255,000
Common shares issuable under deferred unit awards		72,142		21,183